Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

The following study was conducted at a poultry processing plant under federal inspection, located in the central region of the state of Rio Grande do Sul, Brazil. Its daily slaughters ...